Full metadata record
DC FieldValueLanguage
dc.creatorVallejo-Valdivielso, M. (María)-
dc.creatorCastro-Manglano, P. (Pilar) de-
dc.creatorDíez-Suárez, A. (Azucena)-
dc.creatorMarín-Méndez, J.J. (J. J.)-
dc.creatorSoutullo-Esperón, C. (César Alejandro)-
dc.date.accessioned2022-06-09T12:15:51Z-
dc.date.available2022-06-09T12:15:51Z-
dc.date.issued2019-
dc.identifier.citationVallejo-Valdivielso, M. (María); Castro-Manglano, P. (Pilar) de; Díez-Suárez, A. (Azucena); et al. "Clinical and neuropsychological predictors of methylphenidate response in children and adolescents with ADHD: A naturalistic follow-up study in a spanish sample". Clinical Practice & Epidemiology in Mental Health. 15, 2019, 160 - 171es
dc.identifier.issn1745-0179-
dc.identifier.urihttps://hdl.handle.net/10171/63633-
dc.description.abstractBackground: Methylphenidate (MPH) is the most commonly used medication for Attention-Deficit/Hyperactivity Disorder (ADHD), but to date, there are neither consistent nor sufficient findings on conditions differentiating responsiveness to MPH response in ADHD. Objective: To develop a predictive model of MPH response, using a longitudinal and naturalistic follow-up study, in a Spanish sample of children and adolescents with ADHD. Methods: We included all children and adolescents with ADHD treated with MPH in our outpatient Clinic (2005 to 2015), evaluated with the K-SADS interview. We collected ADHD-RS-IV.es and CGI-S scores at baseline and at follow up, and neuropsychological testing (WISC-IV, Continuous Performance Test (CPT-II) & Stroop). Clinical response was defined as >30% reduction from baseline of total ADHD-RS-IV.es score and CGI-S final score of 1 or 2 maintained for the previous 3 months. Results: We included 518 children and adolescents with ADHD, mean (SD) age of patients was 11.4 (3.3) years old; 79% male; 51.7% had no comorbidities; and 75.31% had clinical response to a mean MPH dose of 1.2 mg/kg/day. Lower ADHD-RS-IV.es scores, absence of comorbidities (oppositional-defiant symptoms, depressive symptoms and alcohol/cannabis use), fewer altered neuropsychological tests, higher total IQ and low commission errors in CPT-II, were significantly associated with a complete clinical response to methylphenidate treatment. Conclusion: Oppositional-defiant symptoms, depressive symptoms, and a higher number of impaired neuropsychological tests are associated with worse clinical response to methylphenidate. Other stimulants or non-stimulants treatment may be considered when these clinical and neuropsychological variables converged in the first clinical interviewes_ES
dc.description.sponsorshipMaría Vallejo-Valdivielso, MD has received research funds for her department (non-personal) from Caja Navarra Foundation (CAN), Vasco-Navarra Society of Psychiatry (SVNP), Government of Navarra and Spanish Society of Child and Adolescent Psychiatry (AEPNYA). She has received financial support on continuous scientific education from Shire, Janssen and Lundbeck. Pilar de Castro-Manglano, MD, PhD has received research funds for her department (non-personal) from Caja Navarra Foundation (CAN), Eli Lilly, Lundbeck and Shire. She has served as Consultant / Advisory Board for: Alicia Koplowitz Foundation, Editorial Médica Panamericana and Eli Lilly. She has served in the Speaker's Bureau / has given talks on Continuous Medical Education (not about a product) for Shire. Azucena Díez-Suárez, MD, PhD has received research funds for her department (non-personal) from Caja Navarra Foundation (CAN), Otsuka Pharmaceutics, Lundbeck and Shire. She has served as Consultant / Advisory Board for: Alicia Koplowitz Foundation and Editorial Médica Panamericana. She has served in the Speaker's Bureau and has given talks on Continuous Medical Education (not about a product) for Shire. Juan J. Marín-Méndez, BsC, PhD has received research funds for his department (non-personal) from Caja Navarra Foundation (CAN), Carlos III Health Institute, Government of Navarra, Qpea Foundation and Shire. He has received financial support for continuous scientific education from Shire, Lilly, Rovi, Roche and Pfizer. César A. Soutullo, MD, PhD has received research funds for his department (non-personal) from Caja Navarra Foundation (CAN), Eli Lilly, Lundbeck, Shire and TEVA. He has served as Consultant / Advisory Board for: Alicia Koplowitz Foundation, Editorial Médica Panamericana, Eli Lilly, EUNETHYDIS (European Network on Hyperkinetic Disorder), Instituto de Salud Carlos III (FIS), NeuroTech Solutions Ltd, Spanish Health Ministry Quality Plan (Clinical Practice Guidelines on TDAH and Clinical Practice Guidelines on Depression), Rubió and Shire. He has served in the Speaker's Bureau / has given talks on Continuous Medical Education (not about a product) for Eli Lilly, Shire, Universidad Internacional Menéndez Pelayo and Universidad Internacional de La Rioja (UNIR). He has received Royalties from: DOYMA, Editorial Médica Panamericana, EUNSA and Mayo Ediciones.es_ES
dc.language.isoenges_ES
dc.publisherBentham Science Publishers Ltd.es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectADHDes_ES
dc.subjectPredictive factorses_ES
dc.subjectNeuropsychological variableses_ES
dc.subjectMethylphenidatees_ES
dc.subjectTreatmentes_ES
dc.subjectSpanish samplees_ES
dc.titleClinical and neuropsychological predictors of methylphenidate response in children and adolescents with ADHD: A naturalistic follow-up study in a spanish samplees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.es_ES
dc.identifier.doi10.2174/1745017901915010160-
dadun.citation.endingPage171es_ES
dadun.citation.publicationNameClinical Practice & Epidemiology in Mental Healthes_ES
dadun.citation.startingPage160es_ES
dadun.citation.volume15es_ES

Files in This Item:
Thumbnail
File
CPEMH-15-160.pdf
Description
Size
626.2 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.